alexa Hepatitis C | Hong Kong| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Hepatitis C

  • Hepatitis C

     Hepatitis C: Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infection is usually asymptomatic, and is only very rarely associated with life-threatening disease. Symptoms: The incubation period for hepatitis C is 2 weeks to 6 months. Following initial infection, approximately 80% of people do not exhibit any symptoms. Those who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea and jaundice (yellowing of skin and the whites of the eyes). Causes: Hepatitis C caused due to contact with contaminated blood or needles used to inject illegal drugs or draw tattoos. 

  • Hepatitis C

    Diagnosis : HCV infection is diagnosed in 2 steps: Screening for anti-HCV antibodies with a serological test identifies people who have been infected with the virus. If the test is positive for anti-HCV antibodies, a nucleic acid test for HCV RNA is needed to confirm chronic HCV infection.Treatment: Hepatitis C does not always require treatment as the immune response in some people will clear the infection, and some people with chronic infection do not develop liver damage. 

  • Hepatitis C

    Pathophysiology : Each of the hepatitis viruses causes similar liver damage. The inflammatory process is activated throughout the whole liver, and hepatocytes are destroyed by cytotoxic cytokines and natural killer cells, both parts of the inflammatory process. Cellular necrosis takes place. If inflammation affects the periportal areas, cholestasis, or the interruption of the flow of bile takes place. 

  • Hepatitis C

    statistics: The prevalence of anti-HCV among voluntary blood donors is stable, remaining at approximately 0.035–0.099% over the past 10 years, and is higher in the older age group. Among the high-risk groups, the anti-HCV prevalence is as follows: (1) hospital patients 0.8%, (2) intravenous drug users 46.0%, (3) patients infected with HIV 7.9%, (4) children with transfusion-dependent hematologic disease 16.3%, (5) patients with hepatocellular carcinoma 7.3%. Among blood donors, 58.8% were infected with HCV genotype 1b and 27.0% with genotype 6a. Genotype 6a is particularly common among intravenous drug users. 

Expert PPTs
Speaker PPTs